From JAK to CALR: redefining therapeutic targets in myeloproliferative neoplasms.

Abstract excerpt

This review highlights the emergence of CALR as a promising therapeutic target in CALR-mutated myeloproliferative neoplasms. While current JAK inhibitors alleviate symptoms and reduce thrombosis risk, they lack clonal specificity, have a limited impact on the natural history of disease, and are limited by toxicity and resistance. In contrast, CALR mutations generate a unique, disease-specific neoepitope that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Calreticulin
• Share to CALR gene
• Share to MPL gene